natgillin/translations-raw huggingface dataset:
Forekomst (%) af bekræftet natligb hypoglykæmi (n/Total N)
Incidence (%) of confirmed nocturnalc hypoglycaemia (n/Total N)
Forekomst (%) af bekræftetb hypoglykæmi (n/Total N)
Incidence (%) of confirmedb hypoglycaemia (n/Total N)
Forekomst af alle apopleksier og intrakranielle blødninger
Incidence of total strokes and intracranial haemorrhage
Forekomst af autotransplantation
Incidence of autograft
Forekomst af bivirkninger, herunder grad  3 bivirkninger og alvorlige bivirkninger var sammenlignelige mellem de to behandlingsarme.
The incidence of AEs, including Grade  3 AEs and SAEs, was similar between the two treatment arms.
Forekomst af cirrose
Presence of cirrhosis
Forekomst af CYP2C19 fænotype og genotype
CYP2C19 Phenotype and Genotype Frequency
Forekomst af cytopenier afhang tydeligvis også af sygdommens stadie.
However, the occurrence of cytopaenias was also clearly dependent on the stage of the disease.
Forekomst af disse metabolitter i urinen sammen med en høj total clearance fra organismen og lav udskillelse med urinen af uomdannet lægemiddel (~4 % af dosis) indikerer, at decitabin i væsentlig grad omdannes in vivo.
The presence of these metabolites in urine together with the high total body clearance and low urinary excretion of unchanged drug in the urine (~4% of the dose) indicate that decitabine is appreciably metabolized in vivo.
Forekomst af eller risiko for venøs tromboemboli (VTE).
Presence or risk of venous thromboembolism (VTE)
Forekomst af FEV1-reduktion > 15% fra baseline efter indgivelse af Rapiscan blev vurderet i tre randomiserede, kontrollerede kliniske studier.
The incidence of a FEV1 reduction > 15% from baseline after Rapiscan administration was assessed in three randomised, controlled clinical studies.
Forekomst af frakturer.
Incidence of fractures.
Forekomst af grad 3 og 4 bivirkninger (<50.000/mm3) var 8,7% hos patienter behandlet med trastuzumabemtansin og uafhængig af etnicitet.
Independent of race, the incidence of Grade 3 or 4 events (< 50,000/mm3) was 8.7% in patients treated with trastuzumab emtansine.
Forekomst af HACA kan være forbundet med forværring af infusions- eller allergiske reaktioner efter den anden infusion ved efterfølgende behandlingsserier.
The presence of HACA may be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses.
Forekomst af HLA-B*1502 hos personer af hankinesisk eller thailandsk oprindelse er vist at være stærkforbundet med risikoen for at udvikle de alvorlige hudreaktioner, der er kendt som Stevens- Johnsons syndrom (SJS), når disse personer behandles med carbamazepin.
HLA-B* 1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing the severe cutaneous reactions known as Stevens Johnson syndrome (SJS) when treated with carbamazepine.
Forekomst af HLA-B*1502 hos personer af hankinesisk eller thailandsk oprindelse er vist at være stærkt forbundet med risikoen for at udvikle de alvorlige hudreaktioner, der er kendt som Stevens- Johnsons syndrom (SJS), når disse personer behandles med carbamazepin.
HLA-B* 1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing the severe cutaneous reactions known as Stevens Johnson syndrome (SJS) when treated with carbamazepine.
Forekomst af HLA-B*1502-allel hos personer af hankinesisk eller thailandsk oprindelse har vist sig at være tæt forbundet med risikoen for at få Stevens-Johnsons syndrom (SJS) under behandling med carbamazepin.
HLA-B*1502 allele in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing Stevens-Johnson syndrome (SJS) when treated with carbamazepine.
Forekomst af hudsymptom(er):
Occurrence of skin symptom(s):
Forekomst af huller i tarmvæggen (gastrointestinal perforation).
Occurrence of holes in the wall of your gut (gastrointestinal perforation)
Forekomst af laktacidose kan og bør reduceres ved også at vurdere andre associerede risikofaktorer såsom dårligt kontrolleret diabetes, ketose, langvarig faste, meget stort indtag af alkohol, leverinsufficiens samt tilstande associeret med hypoxi.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
forekomst af lægemiddeltoksicitet og om nødvendigt reduktion af dosis.
Vinca alkaloids: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.
Forekomst af osteosarkomer sås udelukkende ved doser, der resulterede i en systemisk eksponering ≥ 27 gange højere end eksponeringen hos mennesker ved en dosis på 100 mikrogram.
The occurrence of osteosarcoma only occurred at doses that produced systemic exposures > 27-times higher than that observed in humans at the 100 micrograms dose.
Forekomst af PN (%)
Incidence of PN (%)
Forekomst af svære infektioner pr. patientår
Rate of severe infections per person year
Forekomst af TMA-
TMA intervention rate
Forekomst af visse bivirkninger
Occurrence of certain side effects
Forekomst hos forsøgsperson
Subject Incidence
Forekomsten af a- GVHD grad I-II var 13 % (8/61), mens forekomsten af grad III-IV var 5 % (3/61).
The incidence of a-GVHD grades I-II was 13% (8/61), while the incidence of grade III-IV was 5% (3/61).
Forekomsten af afvigende, men ikke klinisk signifikante resultater ved brystpalpation og mammografi faldt i ospemifen 60 mg- populationen i løbet af det 1 år lange forsøg (Forsøg 3) henholdsvis fra 1,6% til 0,6% og fra 11,8% til 8,1%.
The incidence of abnormal, but not clinically significant, findings on breast palpation and mammography decreased in the ospemifene 60 mg population during the 1-year study (Trial 3) from 1.6% to 0.6% and from 11.8% to 8.1% respectively.
Forekomsten af aktivitetsneutraliserende antistoffer (inhibitorer) er meget sjældne hos tidligere behandlede patienter, der får faktor IX-produkter.
The occurrence of activity-neutralising antibodies (inhibitors) is a very rare event in previously treated patients receiving factor IX-containing products.
Forekomsten af alle bivirkninger relateret til lever- og galdesystemerne var < 1,5 % i alle behandlingsgrupper og svarende til placebo.
The incidence of all adverse events relating to liver and biliary systems was  1.5% in any treatment group and similar to placebo.
Forekomsten af alle bivirkninger relateret til lever- og galdesystemerne var < 1,5 % i alle behandlingsgrupper, hvilket svarer placebo.
The incidence of all adverse events relating to liver and biliary systems was  1.5% in any treatment group and similar to placebo.
Forekomsten af alle grader af perifer neuropati efter intravenøs administration af bortezomib var lavere i de ældre forsøg med bortezomib administreret intravenøst end i forsøg MMY- 3021.
The incidence of all grade peripheral neuropathy with bortezomib administered intravenously was lower in the historical studies with bortezomib administered intravenously than in study MMY-3021.
Forekomsten af alvorlig hypoglykæmi (antal patienter pr.
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were
Forekomsten af alvorlig hypoglykæmi (antal påvirkede patienter pr.
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were
Forekomsten af alvorlige bivirkninger, der forekom ved alle kliniske undersøgelser, var 2,2 % hos Jetrea-behandlede patienter og 2,4 % hos kontrolpatienter.
The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA treated patients and 2.4% in control patients.
Forekomsten af alvorlige blødninger var højere hos patienter med AP-CML, BP- CML og Ph+ ALL.
The incidence of serious bleeding events was higher in patients with AP-CML, BP-CML and Ph+ ALL.
Forekomsten af alvorlige blødningshændelser (grad ≥3) var 2,1 % hos cabozantinib-behandlede RCC- patienter (7/331).
The incidence of severe haemorrhagic events (Grade ≥ 3) was 2.1% in cabozantinib-treated RCC patients (7/331).
Forekomsten af anafylaksi forblev sjælden mellem de dobbeltblinde og langvarige open-label forsøg.
The occurrence of anaphylaxis remained rare between the double blind and long-term open-label experience.
Forekomsten af angioødem hos patienter, som ikke samtidig tog ACE-hæmmere var den samme for begge grupper.
The incidence of angioedema in patients not taking concomitant ACE inhibitors was the same in both groups.
Forekomsten af anæmi var tilsvarende i begge behandlingsgrupper (7 % vs.
The incidence of anaemia was similar in both treatment groups (7% vs.
Forekomsten af behandlingsinducerede/forhøjede anti-rHuPH20-antistoffer var 10,6 % og var kun målt i den sukutane gruppe.
2.4% subcutaneous The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies, only measured in patients in the subcutaneous arm was 10.6%.
Forekomsten af behandlingsinducerede/forhøjede anti-rHuPH20-antistoffer var 6 % i den intravenøse gruppe sammenlignet med 9 % i den sukutane gruppe, og ingen af de patienter, som blev testet positive for anti-rHuPH20-antistoffer, blev testet positive for neutraliserede antistoffer.
The incidence of treatment-induced/enhanced anti-rHuPH20 antibodies was 6% in the intravenous group compared with 9% in the subcutaneous group, and none of the patients who tested positive for anti-rHuPH20 antibodies tested positive for neutralizing antibodies.
Forekomsten af behandlingskrævende udbrud af urinsyregigt var lav og sammenlignelig med placebo i de sidste 6 måneder af de randomiserede studier (efter seponering af urinsyregigtprofylakse) med medianscoren nul.
The rates of gout flare requiring treatment were low and comparable to placebo in the last 6 months of the randomised trials (after gout flare prophylaxis was discontinued) with median scores of zero.
Forekomsten af bivirkninger (f.eks. hypoglykæmi) er afhængig af baggrundsbehandlingen, og bivirkninger er derfor anført for de enkelte behandlingsregimer (monoterapi, tillægsbehandling til metformin, til metformin plus sulfonylurinstof og til insulin).
Due to the impact of the background therapy on adverse reactions (e.g. on hypoglycaemias), adverse reactions were analysed and displayed based on the respective treatment regimens (monotherapy, add- on to metformin add-on to meformin plus sulphonylurea, and add-on to insulin).
Forekomsten af bivirkninger efter indgivelse lokalt i øjet er lavere end efter indgivelse f.eks. gennem munden, eller når det indsprøjtes.
The incidence of side effects after topical ophthalmic administration is lower than when medicines are, for example, taken by mouth or injected.
Forekomsten af bivirkninger er blevet evalueret i et klinisk studie (Studie V87P6) hos børn (6 måneder til 17 år gamle): Uanset alder var reaktogeniciteten højere efter den første dosis end efter den anden vaccination.
The incidence of adverse reactions has been evaluated in one clinical trial (Study V87P6) in children (6 months to 17 years old): Regardless of age, reactogencity was higher after the first dose than after the second vaccination.
Forekomsten af bivirkninger er blevet evalueret i syv kliniske studier hos voksne (18 år og derover) omfattende over 4.300 voksne og ældre, der fik AFLUNOV (mindst 7,5 µg HA, adjuveret).
The incidence of adverse reactions has been evaluated in seven clinical trials in adults (18 years old and above) involving over 4,300 adults and elderly receiving AFLUNOV (at least 7.5 µg HA, adjuvanted).
Forekomsten af bivirkninger er blevet vurderet i kliniske studier hos 59 voksne fra 18 til 49 år, som fik mindst én dosis Pandemisk influenzavaccine H5N1 MedImmune.
Clinical studies have evaluated the incidence of adverse reactions in 59 adults from 18 to 49 years of age receiving at least one dose of Pandemic influenza vaccine H5N1 MedImmune.
Forekomsten af bivirkninger herunder udtrykkes i henhold til følgende kategorier:
The incidence of the adverse reactions below are expressed according to the following categories:
Forekomsten af bivirkninger i bivirkninger generelt, bivirkninger i centralnervesystemet og især somnolens blev forøget ved behandling af central neuropatisk smerte på grund af rygmarvsskade.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Forekomsten af bivirkninger i centralnervesystemet og især somnolens var generelt øget ved behandling af centrale neuropatiske smerter, der skyldes rygmarvsskader.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury.
Forekomsten af bivirkninger i kontrollerede kliniske forsøg og efter markedsføring:
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Forekomsten af bivirkninger og unormale laboratoriefund (bortset fra stigninger i ALAT og CPK, se nedenfor) var ens for patienter, som blev behandlet med henholdsvis lamivudin og placebo.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients.
Forekomsten af bivirkninger og unormale laboratoriefund (bortset fra stigninger i ALAT og CPK, se nedenfor) var ens mellem de patienter, som blev behandlet med henholdsvis lamivudin og placebo.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients).
Forekomsten af bivirkninger under Fabrazyme-behandling
Incidence of adverse reactions with Fabrazyme treatment
Forekomsten af bivirkninger, der betragtes som relateret til behandling med Nespo i kontrollerede kliniske studier, er:
Incidence of undesirable effects considered related to treatment with Nespo from controlled clinical studies are:
Forekomsten af bivirkninger, der blev indberettet efter de enkelte vaccinationsdoser (dvs.
The adverse reaction rates reported after either vaccination dose (i.e.
Forekomsten af brystsymptomer og uterin blødning var hos raloxifenbehandlede kvinder signifikant lavere end hos kvinder, som blev behandlet med den ene eller anden form for hormonal substitutions- behandling.
The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.
Forekomsten af CAN/IFTA i år 1 ved studie 1 og 2 var numerisk lavere med belatacept end med ciclosporin (henholdsvis ~ 9,4% og 5%).
The prevalence of CAN/IFTA at Year 1 in Studies 1 and 2, was numerically lower with belatacept than ciclosporin (~ 9.4% and 5%, respectively).
Forekomsten af den første episode af akut mellemørebetændelse forårsaget af S. pneumoniae var omtrent halveret hos de børn, der havde fået vaccinen, sammenlignet med de børn, der havde fået sammenligningsvaccinen.
The occurrence of the first episode of acute otitis media caused by S. pneumoniae was approximately halved among children who were given the vaccine compared with those given the comparator.
Forekomsten af diarré, svimmelhed, asteni, vægttab og dehydrering var øget med ≥5 % hos ældre personer sammenlignet med yngre patienter.
The incidence of diarrhoea, dizziness, asthenia, weight decrease, and dehydration was increased by ≥5% in older people compared to younger patients.
Forekomsten af disse hændelser kan kædes sammen med udviklingen af patientens sygdom.
The occurrence of these events may be linked to the patients’ disease evolution.
Forekomsten af disse yderligere RAS-mutationer (KRAS-exon 3, 4 og NRAS-exon 2, 3, 4) i populationen med vildtype-KRAS (exon 2) var cirka 19 %.
The incidence of these additional RAS mutations (KRAS exons 3, 4 and NRAS exons 2, 3, 4) in the wild-type KRAS (exon 2) population was approximately 19%.
Forekomsten af dødelige VTE’er var sammenlignelig i de to arme (0,2 %).
The incidence of fatal VTEs was similar between arms (0.2%).
Forekomsten af dødsfald var dog højere hos olanzapin-behandlede patienter end hos patienter, behandlet med placebo, uafhængig af disse risikofaktorer.
However, the incidence of death was higher in olanzapine- treated than in placebo-treated patients independent of these risk factors.
Forekomsten af dødsfald var dog højere hos olanzapin-behandlede patienter end hos patienter, behandlet med placebo, uafhængig af disse risikofaktorer.
However, the incidence of death was higher in olanzapine-treated than in placebo- treated patients independent of these risk factors.
Forekomsten af dødsfald var dog højere hos olanzapinbehandlede patienter end hos patienter, behandlet med placebo, uafhængig af disse risikofaktorer.
However, the incidence of death was higher in olanzapine- treated than in placebo-treated patients independent of these risk factors.
Forekomsten af dødsfald var dog højere hos olanzapinbehandlede patienter end hos patienter, behandlet med placebo, uafhængig af disse risikofaktorer.
However, the incidence of death was higher in olanzapine-treated than in placebo- treated patients independent of these risk factors.
Forekomsten af en bivirkning hos en enkelt patient er defineret som ”ikke almindelig” set i lyset af det relativt begrænsede antal behandlede patienter.
The occurrence of an adverse reaction in a single patient is defined as uncommon in light of the relatively small number of patients treated.
Forekomsten af et QTcF-interval > 500 msek. var ualmindelig og blev observeret hos én patient (1/321 patienter).
The incidence of a QTcF interval >500 msec was uncommon and observed in one patient (1/321 patients).
Forekomsten af forhøjet ikke- konjugeret bilirubin var lavere hos forsøgspersoner, der ikke fik ribavirin.
The frequency of indirect bilirubin elevations was lower among subjects who did not receive ribavirin.
Forekomsten af frakturer hos postmenopausale kvinder:
Fracture Incidence in Postmenopausal Women:
Forekomsten af følgende bivirkninger (alle grader): letargi, stomatitis, neutropenisk infektion var ≥ 10
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates
Forekomsten af gastrointestinale-vaginale fistler hos patienter, som var behandlet med Avastin+kemoterapi, var højere hos patienter med recidiv indenfor strålefeltet af tidligere strålebehandling (16,7%) sammenlignet med patienter med recidiv udenfor strålefeltet af tidligere strålebehandling (3,6%).
The frequency of GI-vaginal fistulae in the group treated with Avastin + chemotherapy was higher in patients with recurrence within the field of prior radiation (16.7%) compared with patients with recurrence outside the field of prior radiation (3.6%).
Forekomsten af grad 3 hånd-fod-hudreaktion var 16,6 % (KRC) og 22,0 % (GIST).
The incidence of Grade 3 hand-foot skin reaction was 16.6% (CRC) and 22.0% (GIST).
Forekomsten af grad 3 og grad 4 neutropeni var højere hos gruppen, der var i kombinationsbehandling end i monoterapi-gruppen (28 % vs.
The incidence of grade 3 and 4 neutropaenia was higher in the combination therapy group than in the monotherapy group (28% vs.
Forekomsten af grad 3 og grad 4 trombocytopeni var højere hos gruppen, der var i kombinationsbehandling end i monoterapi-gruppen (22 % vs.
The incidence of grade 3 and 4 thrombocytopaenia was higher in the combination therapy group than in the monotherapy group (22% vs.
Forekomsten af grad ≥3 neutropeni var højere i gruppen med høj trifluridin-AUC (47,8%) i forhold til gruppen med lav trifluridin-AUC (30,4%).
The incidences of Grade ≥3 neutropenia were higher in the high-trifluridine AUC group (47.8%) compared with the low-trifluridine AUC group (30.4%).
Forekomsten af hjerteinsufficiens i det dobbeltblinde hovedstudie var 1,4 % ved tripel- kombinationsbehandling, sammenlignet med 0,4 % for kombinationsbehandling med metformin og sulfonylurinstof.
The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy.
Forekomsten af hjerteinsufficiens i det dobbeltblinde hovedstudie var 1,4 % ved tripel- kombinationsbehandling, sammenlignet med 0,4 % for metformin og sulfonylurinstof kombinationsbehandling.
The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy.
Forekomsten af hjerteinsufficiens var 2,4 % ved kombinationbehandling med insulin (rosiglitazon givet for at understøtte insulinbehandling), sammenlignet med 1,1 % ved behandling med insulin alene.
The incidence of heart failure in combination with insulin (rosiglitazone added to established insulin therapy) was 2.4%, compared to insulin alone, 1.1%.
Forekomsten af hvæsen inden for 15 dage efter vaccinationen var lavere hos dem, der havde fået Fluenz, i forhold til dem, der havde fået inaktiveret vaccine (19,5 % i forhold til 23,8 %, P=0,02).
The incidence of wheezing within 15 days after vaccination was lower in Fluenz recipients relative to inactivated vaccine recipients (19.5% vs.
Forekomsten af hvæsende vejrtrækning inden for 15 dage efter vaccination var lavere hos T/LAIV-vaccinerede end hos børn og unge, der blev vaccineret med den sæsonbetingede inaktiverede influenzavaccine (19,5 % vs.
The incidence of wheezing within 15 days after vaccination was lower in T/LAIV recipients relative to seasonal inactivated vaccine recipients (19.5% vs.
Forekomsten af hypertension af grad 3 var 7,6 % (KRC) og
The incidence of Grade 3 hypertension was 7.6% (CRC) and 27.3% (GIST).
Forekomsten af hypoglykæmi var lav (1,4%) hos forsøgspersoner i saxagliptin plus dapagliflozin plus metformin-gruppen.
The incidence of hypoglycaemia was low (1.4 %) in subjects treated with saxagliptin plus dapagliflozin plus metformin group.
Forekomsten af hypoglykæmi var signifikant lavere i vildagliptin-gruppen (1,7 %) end i glimepirid- gruppen (16,2 %).
The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%).
Forekomsten af investigator-indberettede kardiovaskulære APTC-hændelser i de kombinerede fase 3-studier (APEX, FACT og CONFIRMS) var 0,7 versus 0,6 hændelser pr.
The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs.
Forekomsten af kardiovaskulære bivirkninger i fase 3-studierne med patienter, der fik abirateronacetat, versus patienter, der fik placebo, var følgende: hypertension 14,5 % vs.
The incidence of cardiovascular adverse reactions in the phase 3 studies in patients taking abiraterone acetate versus patients taking placebo were as follows: hypertension 14.5% vs.
Forekomsten af kvalme var 24,5 % i lixisenatidgruppen sammenlignet med 35,1 % i exenatid to gange dagligt-gruppen, og forekomsten af symptomatisk hypoglykæmi med lixisenatid var 2,5 % i den 24- ugers behandlingsperiode sammenlignet med 7,9 % i exenatidgruppen.
The incidence of nausea was 24.5% in the lixisenatide group compared to 35.1% in the exenatide twice daily group and the incidence of symptomatic hypoglycaemia with lixisenatide was 2.5% during the 24-week main treatment period compared to 7.9% in the exenatide group.
Forekomsten af laktacidose kan og bør reduceres ved også at bedømme andre relaterede risikofaktorer såsom dårligt reguleret diabetes, ketose, længerevarende faste, overdrevet alkoholindtag, leverinsufficiens samt enhver tilstand, der er forbundet med hypoxi.
The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.